14 Jun Drug Discovery News: A cell therapy to heal a broken heart
Researchers harvest stem cells from patients who have recently had a heart attack and use them to trigger regeneration of their cardiac muscle.
Author: equipe
13 Jun Drug Development & Delivery: CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.
18 May EPR: Cell therapy could help curb progression of heart failure
New clinical trial data demonstrates the potential for a stem cell treatment as a cardiac regenerative therapy.
14 May CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction
/*! elementor - v3.21.0 - 08-05-2024 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Positive changes in prognostic biomarkers including...
06 May CellProthera to share results from its Phase I/IIb study investigating the safety and efficacy of ProtheraCytes (CD34+ expanded stem cells) in Acute Myocardial Infarction
Mulhouse, France, April 23 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases will...
16 Apr DDW: 2024 predictions: Experts weigh in on stem cells
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future of stem cells in drug discovery.
16 Apr EUROPEAN PHARMACEUTICAL MANUFACTURER: Optimising TIME-TO-MARKET for innovative cell therapy
Didier HAGUENAUER - CMO - CELLPROTHERA
29 Feb CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases
- Upcoming clinical trials, led by stem cell pioneer Professor Takayuki Asahara, will use CellProthera’s StemXpand® and StemPack® technology to manufacture endothelial progenitor cells (EPCs)
- This collaboration is the first to bring CellProthera’s manufacturing systems to Japan, following successful use of the systems in clinical trials in Europe
29 Feb PHARMIWEB: CellProthera collaborates with Japanese stem cell experts…
CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases
10 Nov LE FIGARO | DOSSIER SANTE – Stem cells : a promise that is becoming a reality
A 20 year old promise slowly becoming a reality